Khanna D, Tashkin DP, Wells AU, et al. - Good tolerability of abituzumab was evident with no new safety signals observed in patients with systemic sclerosis–associated interstitial lung disease (SSc-ILD) treated with it. Abituzumab merits further investigation as a treatment option for SSc-ILD.

• Patients (≤ 75 yrs) with SSc-ILD on stable mycophenolate were randomly assigned (2:2:1) to receive intravenous abituzumab 1500 mg, abituzumab 500 mg, or placebo every 4 weeks for 104 weeks.

• The annual rate of alteration in absolute forced vital capacity was set as the primary endpoint.

• Premature termination of the study was attributed to slow enrollment (n = 75 screened, n = 24 randomized), precluding robust analysis of efficacy.